Contraindicated (1)bortezomib will boost the degree or impact of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Powerful or moderate CYP2C19 inhibitors may improve mavacamten systemic publicity, leading to heart failure as a result of systolic dysfunction.B: Could be acceptable. Possibly animal experiments exhibit no ch